Abstract
Vasovagal syncope (VVS) is a common clinical problem that significantly reduces quality of life yet lacks effective medical therapies. Midodrine is an alpha1-adrenergic receptor agonist pro-drug with a short half-life that requires a multiple dose regimen. Existing literature suggests that midodrine might provide effective suppression of recurrent VVS, but studies have used heterogeneous methods and have yielded inconsistent results. The objective of this systematic review was to evaluate the efficacy of midodrine to prevent syncope in patients with recurrent VVS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
